- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06175949
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Oral Doses of HRS-7085 Tablets in Healthy Subjects, With Assessment of Food Effects
December 10, 2023 updated by: Shandong Suncadia Medicine Co., Ltd.
A Randomized, Double-Blind, Dose-Escalation, Placebo-Controlled Phase I Clinical Trial Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS-7085 Tablets Following Single and Multiple Oral Administrations, With Evaluation of Food Effects in Healthy Subjects
This is a multicenter, randomized, double-blind, placebo-parallel-controlled, Phase I clinical trial investigating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single and multiple oral doses of HRS-7085 tablets in healthy subjects, with assessment of food effects
Study Overview
Status
Not yet recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
70
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Xin Gao
- Phone Number: 0518-82342973
- Email: xin.gao.xg26@hengrui.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Yes
Description
Inclusion Criteria:
- Adults aged 18 to 55 years (inclusive), of any gender (each dose group should include at least two subjects of a single gender, except for the 2 mg dose group in Part 1A).
- Body Mass Index (BMI = weight/height^2) during screening: 19 ≤ BMI < 28 kg/m^2; male weight ≥ 50.0 kg and < 90.0 kg, female weight ≥ 45.0 kg and < 90.0 kg.
- Healthy subjects with physical examination, vital signs, and laboratory test results (including complete blood count, urinalysis, blood biochemistry, coagulation function, thyroid function), chest X-ray, 12-lead electrocardiogram, abdominal ultrasound, judged by the investigator as normal or clinically insignificant abnormalities during screening.
- Female subjects of reproductive potential and male subjects with female partners of reproductive potential must have no plans for reproduction, sperm/egg donation for at least 3 months after the last dose and voluntarily agree to use effective contraception. Serum pregnancy test for female subjects must be negative and not in lactation.
- Obtain informed consent before any trial-related activities begin, fully understand the purpose and significance of this trial, and be willing to comply with the trial protocol.
Exclusion Criteria:
- Within the past year prior to screening or dosing, individuals with systemic diseases such as cardiovascular, hepatic, renal, gastrointestinal, psychiatric, neurological, or hematologic conditions, deemed by the investigator to pose potential safety risks.
- Within the past 6 months prior to screening or dosing, individuals with a history of severe infections (such as bloodstream infections, central nervous system infections, abdominal infections, etc.), severe trauma, or major surgeries (excluding appendectomy); those planning to undergo surgery during the trial.
- Within the past month prior to screening or dosing, individuals with a history of infections (viral, bacterial, fungal, parasitic) requiring systemic antimicrobial therapy.
- Individuals experiencing frequent headaches, nausea, and/or vomiting with a frequency of ≥3 times per month.
- Individuals with allergic tendencies, such as a history of asthma, atopic dermatitis, chronic urticaria, allergic rhinitis, or any known allergies to drugs or foods.
- Within the past month prior to screening or dosing, individuals who donated blood or experienced blood loss ≥200 mL, or within the past 3 months prior to dosing, individuals who donated blood or experienced blood loss ≥400 mL.
- As determined by the study physician, individuals with any physiological or psychological condition that may increase trial risks, affect subject compliance with the protocol, or interfere with subject completion of the trial.
- Individuals with a smoking history within the past 3 months prior to screening (average daily smoking >5 cigarettes) or those unable to abstain from any tobacco products during the trial.
- Within the past month prior to screening, individuals with an average daily alcohol intake exceeding 7 g for females (equivalent to approximately 200 mL of beer, 70 mL of wine, or 22 mL of spirits) or exceeding 14 g for males (equivalent to approximately 400 mL of beer, 140 mL of wine, or 45 mL of spirits); or individuals with a positive alcohol test at screening or those unable to abstain from alcohol during the trial.
- Individuals who consumed any grapefruit-containing foods or beverages within 7 days prior to taking the study drug, or those who consumed caffeine-containing foods or beverages within 2 days prior to taking the study drug.
- Individuals with special dietary requirements who cannot adhere to a standardized diet.
- Individuals with a history of drug abuse or substance misuse, or those with a positive urine drug screen at screening.
- Individuals with positive results in infectious disease screening tests (HBsAg, anti-HCV Ab, anti-TP Ab, anti-HIV Ab) at screening.
- Individuals with alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), or total bilirubin (TBIL) levels ≥1.5 times the upper limit of normal (ULN) at screening.
- Within 2 weeks prior to screening or dosing, individuals who used any prescription medications, over-the-counter medications, or herbal supplements; or individuals within 5 half-lives of a drug (whichever is longer) at screening or planning to use non-study investigational drug during the trial.
- Within the past 3 months prior to screening, individuals who participated in any other clinical trial (excluding those who failed screening) or those still within 5 half-lives of a drug (whichever is longer) at screening.
- Within the past 3 months prior to screening, individuals who received a live vaccine or attenuated live vaccine, or those planning to receive any vaccines during the trial.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: HRS-7085
|
HRS-7085 Tablets, PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD,
|
Placebo Comparator: HRS-7085 simulant
|
PO, 2mg、5mg、8mg、10mg、12mg、15mg, QD
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events
Time Frame: 7 days or 20 days,
|
7 days or 20 days,
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Estimated)
December 1, 2023
Primary Completion (Estimated)
June 1, 2024
Study Completion (Estimated)
July 1, 2024
Study Registration Dates
First Submitted
December 10, 2023
First Submitted That Met QC Criteria
December 10, 2023
First Posted (Estimated)
December 19, 2023
Study Record Updates
Last Update Posted (Estimated)
December 19, 2023
Last Update Submitted That Met QC Criteria
December 10, 2023
Last Verified
December 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HRS-7085-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Inflammatory Bowel Disease
-
Centre Hospitalier Universitaire, AmiensFunding from DGOS (PHRC IR 2013 and PRME)CompletedPediatric Inflammatory Bowel DiseaseFrance
-
University of British ColumbiaCompletedInflammatory Bowel Disease 11Canada
-
University of ChicagoTerminatedInflammatory Bowel Disease (IBD)United States
-
University of Wisconsin, MadisonTerminatedInflammatory Bowel Disease (IBD)United States
-
Cedars-Sinai Medical CenterUnknownPediatric Inflammatory Bowel Disease
-
Hull University Teaching Hospitals NHS TrustWellcome/EPSRC Centre for Interventional and Surgical Sciences, University...RecruitingInflammatory Bowel Disease 1United Kingdom
-
Assiut UniversityNot yet recruitingIBD-Inflammatory Bowel Disease
-
University of Wisconsin, MadisonCompletedInflammatory Bowel Disease (IBD)United States
-
Kyungpook National University HospitalDaegu Catholic University Medical Center; Yeungnam University Hospital; DongGuk...RecruitingIdiopathic Chronic Inflammatory Bowel DiseaseKorea, Republic of
-
Assiut UniversityUnknownHepatobilliary Manifestations in Inflammatory Bowel Disease Patients
Clinical Trials on HRS-7085 Tablets
-
Atridia Pty Ltd.CompletedInflammatory Bowel DiseaseAustralia
-
Shandong Suncadia Medicine Co., Ltd.RecruitingAdvanced Malignant TumorChina
-
Chengdu Suncadia Medicine Co., Ltd.Active, not recruitingParoxysmal Nocturnal HemoglobinuriaChina
-
Chengdu Suncadia Medicine Co., Ltd.RecruitingParoxysmal Nocturnal HemoglobinuriaChina
-
Shandong Suncadia Medicine Co., Ltd.Not yet recruiting
-
Shandong Suncadia Medicine Co., Ltd.RecruitingUnresectable or Metastatic Breast CancerChina
-
Shandong Suncadia Medicine Co., Ltd.Enrolling by invitationMetastatic or Local Advanced Breast Cancer of PatientsChina
-
Guangdong Hengrui Pharmaceutical Co., LtdEnrolling by invitationRefractory Chronic CoughChina
-
Jiangsu HengRui Medicine Co., Ltd.Recruiting
-
Grupo Español de Rehabilitación MultimodalUnknownArthroplasty, Replacement, Knee | Arthroplasty, Replacement, HipSpain